Tesamorelin vs CJC-1295
Tesamorelin and CJC-1295 are both growth-hormone-releasing hormone (GHRH) analogs studied for their action on pituitary GHRH receptors. Tesamorelin is described in research as a modified GHRH analog engineered for greater stability than the native hormone, and published reviews describe human clinical research on it, particularly on visceral adipose tissue in HIV-associated lipodystrophy. CJC-1295 without DAC, also called modified GRF 1-29, is characterized by a short half-life; without the drug affinity complex its action is brief, which research associates with preserving natural pulsatile growth hormone release. Human data for the no-DAC form are limited, appearing mainly in reviews and anti-doping detection research, while a small randomized trial studied the long-acting DAC form in healthy adults.
Key differences. In plain words.
- 01
Tesamorelin is characterized as a stabilized GHRH analog, whereas CJC-1295 without DAC is characterized by a short half-life and brief action.
- 02
Tesamorelin is at a late-clinical research stage with published human clinical reviews, while CJC-1295 is at an early-clinical stage, with small human studies mostly involving the long-acting DAC form.
- 03
Tesamorelin research has focused on visceral adipose tissue and related metabolic markers, particularly in HIV-associated lipodystrophy, whereas CJC-1295 research has focused on growth hormone release and preservation of its natural pulsatile pattern.
- 04
CJC-1295 also appears in anti-doping analytical detection research and has been identified in seized doping material, a context not described for tesamorelin.
- 05
Research protocols have used 500–2,000 mcg of tesamorelin once daily in 8-week blocks, compared with 100–300 mcg of CJC-1295 five days per week in 12-week blocks, both followed by 4 weeks off.
Side by side. From the research.
Studied ranges describe what published research protocols have used. They are not instructions or recommendations. Products are sold for research purposes only; each order ships with a protocol guide for the specific product.
Mechanism
How it is thought to work
Tesamorelin
Research describes tesamorelin as a modified GHRH analog with greater stability than the native hormone, studied for pituitary action and downstream metabolic signaling.
Stabilized Analog
Studied as a modified releasing-hormone analog engineered for greater stability in research settings.
Body Composition
Explored in research on visceral adipose tissue and associated metabolic markers.
How it is thought to work
CJC-1295
Research describes it as a GHRH analog acting on pituitary receptors, with the absence of the drug affinity complex keeping its action brief rather than sustained.
GHRH Pathway
Studied as a releasing-hormone analog acting on the pituitary receptors that govern natural hormone pulses.
Short Half-Life
Without DAC its action is brief, which research associates with preserving the body's own pulsatile rhythm.
Ask about Tesamorelin and CJC-1295
Plain answers from our library and the cited studies.
AI answers can be wrong. Research use only.

